• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗击新冠疫情的疫苗正在进行的临床试验。

Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic.

作者信息

Chakraborty Chiranjib, Sharma Ashish Ranjan, Bhattacharya Manojit, Sharma Garima, Saha Rudra P, Lee Sang-Soo

机构信息

Department of Biotechnology, School of Life Science & Biotechnology, Adamas University, Kolkata 700126, India.

Institute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon 24252, Korea.

出版信息

Immune Netw. 2021 Jan 19;21(1):e5. doi: 10.4110/in.2021.21.e5. eCollection 2021 Feb.

DOI:10.4110/in.2021.21.e5
PMID:33728098
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7937508/
Abstract

Coronavirus disease 2019 (COVID-19) has developed as a pandemic, and it created an outrageous effect on the current healthcare and economic system throughout the globe. To date, there is no appropriate therapeutics or vaccines against the disease. The entire human race is eagerly waiting for the development of new therapeutics or vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Efforts are being taken to develop vaccines at a rapid rate for fighting against the ongoing pandemic situation. Amongst the various vaccines under consideration, some are either in the preclinical stage or in the clinical stages of development (phase-I, -II, and -III). Even, phase-III trials are being conducted for some repurposed vaccines like Bacillus Calmette-Guérin, polio vaccine, and measles-mumps-rubella. We have highlighted the ongoing clinical trial landscape of the COVID-19 as well as repurposed vaccines. An insight into the current status of the available antigenic epitopes for SARS-CoV-2 and different types of vaccine platforms of COVID-19 vaccines has been discussed. These vaccines are highlighted throughout the world by different news agencies. Moreover, ongoing clinical trials for repurposed vaccines for COVID-19 and critical factors associated with the development of COVID-19 vaccines have also been described.

摘要

2019冠状病毒病(COVID-19)已发展成为一场大流行疾病,对全球当前的医疗保健和经济体系产生了极大影响。迄今为止,尚无针对该疾病的合适治疗方法或疫苗。全人类都在热切等待针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的新治疗方法或疫苗的研发。目前正在努力快速研发疫苗以应对当前的大流行形势。在正在考虑的各种疫苗中,有些处于临床前阶段或处于研发的临床阶段(I期、II期和III期)。甚至,正在对一些重新利用的疫苗进行III期试验,如卡介苗、脊髓灰质炎疫苗和麻疹-腮腺炎-风疹疫苗。我们重点介绍了COVID-19以及重新利用疫苗的当前临床试验情况。本文还讨论了对SARS-CoV-2可用抗原表位的现状以及COVID-19疫苗不同类型疫苗平台的见解。这些疫苗受到了不同新闻机构在全球范围内的关注。此外,还描述了针对COVID-19重新利用疫苗的正在进行的临床试验以及与COVID-19疫苗研发相关的关键因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6b6/7937508/424b2daa902e/in-21-e5-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6b6/7937508/424b2daa902e/in-21-e5-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6b6/7937508/424b2daa902e/in-21-e5-g001.jpg

相似文献

1
Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic.抗击新冠疫情的疫苗正在进行的临床试验。
Immune Netw. 2021 Jan 19;21(1):e5. doi: 10.4110/in.2021.21.e5. eCollection 2021 Feb.
2
Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2.重新利用儿童疫苗:我们能否训练免疫系统对抗 SARS-CoV-2。
Expert Rev Vaccines. 2021 Sep;20(9):1051-1057. doi: 10.1080/14760584.2021.1960161. Epub 2021 Aug 6.
3
Principles and Challenges in anti-COVID-19 Vaccine Development.抗 COVID-19 疫苗研发的原则与挑战。
Int Arch Allergy Immunol. 2021;182(4):339-349. doi: 10.1159/000514225. Epub 2021 Feb 1.
4
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.SARS-CoV-2 变体和 COVID-19 疫苗:当前的挑战与未来策略。
Int Rev Immunol. 2023;42(6):393-414. doi: 10.1080/08830185.2022.2079642. Epub 2022 May 28.
5
The 2020 race towards SARS-CoV-2 specific vaccines.2020 年抗击 SARS-CoV-2 特异性疫苗竞赛。
Theranostics. 2021 Jan 1;11(4):1690-1702. doi: 10.7150/thno.53691. eCollection 2021.
6
A Revisit to the Research Updates of Drugs, Vaccines, and Bioinformatics Approaches in Combating COVID-19 Pandemic.重新审视抗击新冠疫情中药物、疫苗及生物信息学方法的研究进展
Front Mol Biosci. 2021 Jan 25;7:585899. doi: 10.3389/fmolb.2020.585899. eCollection 2020.
7
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.新冠疫苗的快速研发和早期成功为加速癌症治疗机制带来了希望。
Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1.
8
Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?针对冠状病毒感染的疫苗候选者。COVID-19 处于什么位置?
Viruses. 2020 Aug 7;12(8):861. doi: 10.3390/v12080861.
9
Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials.用于控制2019年新型冠状病毒病(COVID-19)的疫苗和药物疗法:临床试验的系统评价
Cureus. 2020 May 28;12(5):e8342. doi: 10.7759/cureus.8342.
10
Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines.绘制 SARS、MERS 和 SARS-CoV-2 疫苗的技术图谱。
Drug Dev Ind Pharm. 2021 Apr;47(4):673-684. doi: 10.1080/03639045.2021.1908343. Epub 2021 Apr 7.

引用本文的文献

1
Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine development.超越新冠病毒的起源:新冠疫苗研发五年历程中的重要战略层面
Mol Ther Nucleic Acids. 2025 Mar 28;36(2):102527. doi: 10.1016/j.omtn.2025.102527. eCollection 2025 Jun 10.
2
SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)疫苗、疫苗开发技术以及疫情期间疫苗开发的重大努力:吸取的经验教训可能有助于抗击下一次大流行。
Vaccines (Basel). 2023 Mar 17;11(3):682. doi: 10.3390/vaccines11030682.
3

本文引用的文献

1
BCG vaccination induced protection from COVID-19.BCG 疫苗接种可预防 COVID-19。
Indian J Tuberc. 2021 Jan;68(1):119-124. doi: 10.1016/j.ijtb.2020.08.004. Epub 2020 Aug 7.
2
COVID-19 vaccines poised for launch, but impact on pandemic unclear.新冠疫苗即将推出,但对疫情的影响尚不明朗。
Nat Biotechnol. 2020 Nov 25. doi: 10.1038/d41587-020-00022-y.
3
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Can the RBD mutation R346X provide an additional fitness to the "variant soup," including offspring of BQ and XBB of SARS-CoV-2 Omicron for the antibody resistance?
新冠病毒奥密克戎毒株的受体结合域(RBD)突变R346X能否为“变异株混合体”(包括奥密克戎毒株的BQ和XBB亚变体的子代)提供额外的适应性以产生抗体抗性?
Mol Ther Nucleic Acids. 2023 Jun 13;32:61-63. doi: 10.1016/j.omtn.2023.02.030. Epub 2023 Mar 15.
4
Current clinical status of new COVID-19 vaccines and immunotherapy.新型 COVID-19 疫苗和免疫疗法的当前临床状况。
Environ Sci Pollut Res Int. 2022 Oct;29(47):70772-70807. doi: 10.1007/s11356-022-22661-1. Epub 2022 Sep 5.
5
Delta variant (B.1.617.2) of SARS-CoV-2: current understanding of infection, transmission, immune escape, and mutational landscape.德尔塔变异株(B.1.617.2):对新冠病毒感染、传播、免疫逃逸和突变特征的最新认识。
Folia Microbiol (Praha). 2023 Feb;68(1):17-28. doi: 10.1007/s12223-022-01001-3. Epub 2022 Aug 12.
6
A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2.对过去二十年中针对大流行病毒病原体研发的疫苗进行全面概述,包括那些正在针对当前新型SARS-CoV-2进行临床试验的疫苗。
RSC Adv. 2021 Jun 8;11(33):20006-20035. doi: 10.1039/d0ra09668g. eCollection 2021 Jun 3.
7
Comparative genomics, evolutionary epidemiology, and RBD-hACE2 receptor binding pattern in B.1.1.7 (Alpha) and B.1.617.2 (Delta) related to their pandemic response in UK and India.比较基因组学、进化流行病学以及 B.1.1.7(阿尔法)和 B.1.617.2(德尔塔)与它们在英国和印度大流行应对相关的 RBD-hACE2 受体结合模式。
Infect Genet Evol. 2022 Jul;101:105282. doi: 10.1016/j.meegid.2022.105282. Epub 2022 Apr 13.
8
Teaching during COVID-19 pandemic in practical laboratory classes of applied biochemistry and pharmacology: A validated fast and simple protocol for detection of SARS-CoV-2 Spike sequences.新冠疫情期间应用生物化学与药理学实践实验课教学:一种快速简便的 SARS-CoV-2 刺突序列检测验证方法。
PLoS One. 2022 Apr 6;17(4):e0266419. doi: 10.1371/journal.pone.0266419. eCollection 2022.
9
A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations.SARS-CoV-2 及其具有逃逸突变的新兴变异株的免疫逃逸、抗体逃逸、部分疫苗逃逸的详细概述。
Front Immunol. 2022 Feb 9;13:801522. doi: 10.3389/fimmu.2022.801522. eCollection 2022.
10
In vitro induction of interleukin-8 by SARS-CoV-2 Spike protein is inhibited in bronchial epithelial IB3-1 cells by a miR-93-5p agomiR.SARS-CoV-2 刺突蛋白在支气管上皮 IB3-1 细胞中诱导白细胞介素-8 的体外诱导作用被 miR-93-5p 激动剂抑制。
Int Immunopharmacol. 2021 Dec;101(Pt B):108201. doi: 10.1016/j.intimp.2021.108201. Epub 2021 Sep 28.
在年轻和老年成年人中进行的一次单盲、随机、对照、2/3 期试验中,观察 ChAdOx1 nCoV-19 疫苗在初免-加强免疫方案中的安全性和免疫原性(COV002)。
Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19.
4
Protective immunity against COVID-19: Unravelling the evidences for humoral vs. cellular components.针对新型冠状病毒肺炎的保护性免疫:解读体液免疫与细胞免疫成分的证据
Travel Med Infect Dis. 2021 Jan-Feb;39:101911. doi: 10.1016/j.tmaid.2020.101911. Epub 2020 Nov 10.
5
India's cost-effective COVID-19 vaccine development initiatives.印度具有成本效益的新冠疫苗研发举措。
Vaccine. 2020 Nov 25;38(50):7883-7884. doi: 10.1016/j.vaccine.2020.10.056. Epub 2020 Oct 20.
6
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.《 老年人中新型冠状病毒 mRNA-1273 疫苗的安全性和免疫原性》
N Engl J Med. 2020 Dec 17;383(25):2427-2438. doi: 10.1056/NEJMoa2028436. Epub 2020 Sep 29.
7
Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19.抗2019冠状病毒病的药物重新利用、现有疫苗及新治疗方法研发计划
Front Pharmacol. 2020 Aug 19;11:1258. doi: 10.3389/fphar.2020.01258. eCollection 2020.
8
SARS-CoV-2 vaccines in development.正在研发中的 SARS-CoV-2 疫苗。
Nature. 2020 Oct;586(7830):516-527. doi: 10.1038/s41586-020-2798-3. Epub 2020 Sep 23.
9
SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients.SARS-CoV-2 检测方法,用于检测在接种疫苗的动物和感染患者中阻断 ACE2 识别的功能性抗体反应。
J Clin Microbiol. 2020 Oct 21;58(11). doi: 10.1128/JCM.01533-20.
10
A SARS-CoV-2 vaccine candidate: cloning and validation.一种新型冠状病毒疫苗候选物:克隆与验证
Inform Med Unlocked. 2020;20:100394. doi: 10.1016/j.imu.2020.100394. Epub 2020 Jul 15.